Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for August 2026

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $101.0 billion at August 31, 2026, a decrease of $1.5 billion from assets under management of $102.5 billion at July 31, 2026. The decrease was due to market depreciation of $1.9 billion and distributions of $155 million, partially offset by net inflows of $528 million.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

SOURCE Cohen & Steers, Inc.

Share this article

NEW YORK, Sept. 9, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the "Class Period"), of the important September 29, 2026 lead plaintiff deadline.

So what: If you purchased Avis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Avis class action, go to https://rosenlegal.com/cases/avis-budget-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 29, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants Pentwater Capital Management LP and Matthew Halbower (Pentwater's CEO, CIO and Founder) orchestrated a scheme to manipulate the market for Avis securities. Taking advantage of Pentwater's position as one of Avis's largest shareholders, holding a total economic interest of approximately 51% of Avis through stocks and cash-settled swaps as of March 2026, defendants' aggressive purchasing of Avis stock during the Class Period triggered unusual volatility and a short squeeze in the market for Avis securities – i.e., a rapid surge in Avis's stock price caused by short sellers buying back shares to cut their losses, thereby fueling further price spikes – all of which served to greatly increase the value of Pentwater's holdings of Avis stock.

To join the Avis class action, go to https://rosenlegal.com/cases/avis-budget-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

Employee-owned Huntsville contractor continues long-standing support of the Missile and Space Intelligence Center.

HUNTSVILLE, Ala., Sept. 9, 2026 /PRNewswire/ -- Radiance Technologies, a 100% employee-owned prime contractor, announced today that it has been selected as an awardee on the $14 billion Contract Operations for Missile Evaluation and Testing (COMET) Multi-Award Task Order Contract (MATOC) supporting the Missile and Space Intelligence Center (MSIC).

"This win belongs to our employee-owners," said Radiance Technologies CEO, Bill Bailey. "They built the technical intelligence expertise that got us here, and now they get to put it to work on a mission that's right in our backyard. We're excited to keep supporting MSIC and the vital work they do for the Warfighter."

Under the contract, Radiance will provide research, development, and sustainment services for new and existing hardware, software, and systems that are foundational to military intelligence upon successful awarded contract.

COMET spans five mission task areas: foundational and technical intelligence analysis, foreign materiel exploitation, information technology operations, modeling and simulation, and business processes. It carries a 10-year period of performance, running from July 21, 2026, through January 1, 2037.

In addition to leading its own team, Radiance holds positions on two other winning COMET teams: one led by SAIC and one through its Radiance Ignite Technologies joint venture.

MSIC, part of the Defense Intelligence Agency, provides policymakers, homeland security and intelligence community organizations, weapons developers, and warfighters with intelligence assessments of foreign weapons systems. This includes. anti-tank guided missiles, ground-based air defense and missile defense systems, short-range and close-range ballistic missiles, and ground-based direct-ascent and directed-energy anti-satellite missile systems.

About Radiance Technologies:

Radiance Technologies is an employee-owned prime contractor founded in 1999 and headquartered in Huntsville, Alabama. Radiance has over 1200 employee-owners across the United States serving the Department of War, the national intelligence community, and other government agencies. From concepts to capabilities, Radiance leads the way in developing customer-focused solutions in the areas of cybersecurity, systems engineering, prototyping, and integration, as well as operational and strategic intelligence, including scientific and technical intelligence. For more information, please visit www.radiancetech.com.

Media Contact:

Julia Parrish

Director, Strategic Branding & Communications

[email protected]

SOURCE Radiance Technologies

Share this article

Vortex returns 30.5 meters at 780.53 g/t silver and 6.1 meters at 21.12 g/t gold

Brimstone extends north with 5.5 meters at 1,345.27 g/t silver

WINNEMUCCA, Nev., Sept. 9, 2026 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or "the Company") announces additional drill results from the 2025-2026 Exploration Drill Program (the "Drill Program") at the Hycroft Mine, located in Nevada, USA, a Tier-1 mining jurisdiction.

Vortex Drill Highlights:

- H26D-6090: 30.5 meters at 780.53 g/t silver and 0.49 g/t gold

- Including 11.2 meters at 1,664.80 g/t silver and 0.85 g/t gold

- Also including 5.5 meters at 2,249.39 g/t silver and 1.01 g/t gold

- H26D-6166: 20.0 meters at 460.82 g/t silver and 0.32 g/t gold 

- Including 6.1 meters at 952.37 g/t silver and 0.54 g/t gold

- Also including 1.6 meters at 2,650.00 g/t silver and 0.91 g/t gold

- H26D-6172: 6.1 meters at 28.65 g/t silver and 21.12 g/t gold

- Including 1.5 meters at 49.40 g/t silver and 43.00 g/t gold

Brimstone Drill Highlights:

- H26D-6167A: 5.5 meters at 1,345.27 g/t silver and 0.56 g/t gold

- Including 1.8 meters at 4,074.00 g/t silver and 1.43 g/t gold

Diane Garrett, Executive Chairman and CEO, commented: "These are some of the strongest results we've seen from the Drill Program. We're not just confirming the high-grade silver system, we're extending it and are consistently intersecting thick, continuous, high-grade mineralization. We have also intersected a high-grade gold interval higher in the known system that we intend to follow up on as we are seeing an increasing number of higher-grade gold intercepts in this area of Vortex. These results continue to confirm our exploration strategy and underpin the potential for a high-grade underground mine. With the system open in all directions and at depth, we see a clear opportunity for continued expansion and growth of these high-grade mineralized systems."

Drill results can be viewed in 3D using VRIFY at the following link:

https://vrify.com/meetings/recordings/9b47dc5c-bbbe-4db2-a4d5-9040ce5763bc

Table 1. Drill Intercept Highlights

Vortex Results

Hole H26D-6090 and H26D-6166 returned 30.5 meters at 780.53 g/t silver and 20.0 meters at 460.82 g/t silver, respectively. Both were drilled offsetting H25D-6070 and H25D-6072 and connect that 2025 step-out drilling to the main Vortex trend. Mineralization remains open to the west, down dip along the Central and Albert faults, currently interpreted as two of the more productive feeder structures at Vortex, and to the north and south.

Holes H26D-6172 tested the northern flank of Vortex and hit four separate silver intervals down hole in the footwall of the Break fault: 23.0 meters at 137.23 g/t silver and 0.69 g/t gold, 12.3 meters at 112.91 g/t silver and 0.25 g/t gold, 21.7 meters at 121.94 g/t silver and 0.89 g/t gold, and 11.1 meters at 177.97 g/t silver and 0.62 g/t gold, demonstrating the vertical continuity and extent of Vortex in this area.

H26D-6173, drilled down dip to the west of H26D-6172, returned 7.4 meters at 134.13 g/t silver, including 2.7 meters at 284.05 g/t silver, and 6.1 meters at 33.99 g/t silver and 2.63 g/t gold. These results further extend the high-grade continuity along the northern flank of the system.

Hole H26D-6172 also returned a high-grade gold interval higher in the hole, 6.1 meters at 21.12 g/t gold, including 1.5 meters at 43.00 g/t gold. This intercept lies higher in the Vortex high-grade silver system. With an increasing number of higher-grade gold intercepts in this area, the Company is planning follow-up drilling to determine the orientation and extent of this mineralization and whether it represents a separate high-grade gold system.

Brimstone Results

At Brimstone, the strategy is to develop the high-grade stockwork vein zone, test the controls on mineralization to the north, south and down dip, and identify and develop high-grade opportunities. Hole H26D-6167A was designed to test and extend high-grade mineralization to the north. The hole encountered a 30-meter silicified breccia that hosted high-grade silver, intersecting 5.5 meters at 1,345.27 g/t silver, including an impressive 1.8 meters at 4,074.00 g/t silver. This intercept opens up additional target opportunities and follow-up drilling is being planned.

Qualified Person

The Company's Qualified Person for exploration is Alex Davidson, Vice President, Exploration, who has reviewed and approved the scientific and technical information contained in this news release.

About Hycroft Mining Holding Corporation

Hycroft Mining Holding Corporation is a US-based gold and silver company exploring and developing the Hycroft Mine, among the world's largest precious metals deposits, located in Nevada, a Tier-1 mining jurisdiction. With a long history of heap leach operations, Hycroft is advancing to the next phase of operations for processing sulfide mineralization. In addition, Hycroft is engaged in a robust exploration drill program (2025-2026 Exploration Drill Program) to expand and advance the two new high-grade silver systems Brimstone and Vortex. These discoveries represent a significant value driver for the Hycroft Mine.

For Further Information

Investor Relations:

E: [email protected]

P: 775-245-0564

Media:

E: [email protected]

P: 775-245-0564

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release and in public statements by our officers or representatives that address activities, events or developments that we expect or anticipate will or may occur in the future are forward-looking statements. These include, but are not limited to, statements regarding future business strategy, plans and goals, competitive strengths, the advancement and development of the Hycroft Mine, the results and implications of metallurgical analysis and test work, and the expansion and growth of our business.

Forward-looking statements are often identified by future or conditional words such as "estimate," "plan," "anticipate," "expect," "intend," "believe," "target," "budget," "may," "can," "will," "would," "could," "should," "seeks," "scheduled to" and similar words or expressions but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties, which could cause actual results to differ materially from those reflected in the statements. The risks include, but are not limited to: (i) risks related to changes in our operations at the Hycroft Mine, including risks associated with the cessation of mining operations at the Hycroft Mine; uncertainties concerning estimates of mineral resources; risks related to the lack of a completed feasibility study; risks related to metallurgical test work and process development; and risks related to our ability to re-establish commercially feasible mining and processing operations; and (ii) industry-related risks, including fluctuations in the price of gold and silver; the commercial success of, and risks related to, our exploration and development activities; uncertainties and risks related to our reliance on contractors and consultants; and the availability and cost of equipment, supplies, energy or reagents.

Any exploration target described in this press release does not represent, and should not be construed to be, an estimate of a mineral resource or mineral reserve. Ranges of potential tonnage and grade (or quality) of an exploration target are conceptual in nature; there has been insufficient exploration of the relevant property or properties to estimate a mineral resource; and it is uncertain if further exploration will result in the estimation of a mineral resource.

These and other risks may cause actual results to differ materially from those expressed or implied by the forward-looking statements, and the occurrence of one or more of these events or circumstances, alone or in combination with others, may have a material adverse effect on our business, cash flows, financial condition and results of operations. Please see the "Risk Factors" outlined in our Annual Report on Form 10-K for the year ended December 31, 2025, and in other reports filed with the SEC, for more information about these and other risks.

Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Although we have attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Although these forward-looking statements are based on assumptions that we believe are reasonable when made, forward-looking statements are not guarantees of future performance and actual results, performance or achievements may differ materially from those made in or suggested by the forward-looking statements in this press release.

Any forward-looking statements made in this press release speak only as of the date of this press release. We undertake no obligation to update these forward-looking statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments, except as required by law.

SOURCE Hycroft Mining Holding Corporation

Share this article

Key Takeaways:

- Fazal F. Merchant joined the AT&T Board, effective Sept. 8.

- Merchant will serve on the Audit Committee and the Corporate Development and Finance Committee.

DALLAS, Sept. 9, 2026 /PRNewswire/ -- AT&T (NYSE:T) elected Fazal F. Merchant to its board of directors, effective Sept. 8. He will serve on the Audit Committee and the Corporate Development and Finance Committee.

Merchant most recently served as President and Chief Financial Officer of Wiz, Inc. – a leading cloud and AI security company. He previously was Co-Chief Executive Officer, Chief Operating Officer and Chief Financial Officer of Tanium Inc.

"Fazal is a great addition to our board, bringing deep expertise across corporate development, finance and technology," said John Stankey, AT&T Chairman and CEO. "Fazal's experience scaling high-growth businesses and helping companies navigate periods of transformation will be invaluable as we continue to evolve, invest for growth, and create long-term value for our shareholders."

Merchant previously held senior leadership roles at DreamWorks Animation and DIRECTV, including Chief Financial Officer of DIRECTV Latin America. During his tenure at both companies, he oversaw major strategic transactions. Earlier, he worked in investment banking at Barclays Capital and the Royal Bank of Scotland. He began his career at Ford Motor Company.

Merchant serves on the board of Warner Bros. Discovery and previously served on the boards of Ariel Investments, Ryman Hospitality Properties, Inc. and Meritor, Inc. He also spent several years serving as a senior advisor to Sixth Street Partners.

Merchant holds a Bachelor of Business Administration from The University of Texas at Austin and an MBA from Indiana University.

To automatically receive AT&T financial news by email, please subscribe to email alerts.

About AT&T

We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 150 years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at about.att.com. Investors can learn more at investors.att.com.

© 2026 AT&T Intellectual Property. All rights reserved. AT&T and the Globe logo are registered trademarks of AT&T Intellectual Property.

SOURCE AT&T

Share this article

DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient management

DecisionDx-SCC's Class 1A (low risk) result demonstrated a 97.3% negative predictive value, supporting confidence in de-escalation decisions, while its Class 2B (highest risk) result identified patients most likely to benefit from adjuvant radiation therapy

FRIENDSWOOD, Texas, Sept. 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC).1

DecisionDx-SCC analyzes 40 genes to provide results related to prognosis and response to adjuvant radiation therapy (ART) based on an individual patient's tumor biology. The enhanced algorithm integrates the molecular data with five clinicopathologic risk factors (immunosuppression, tumor diameter, histological differentiation, perineural invasion and anatomic site) using optimized nested predictive models. This integrated approach provides a comprehensive assessment of metastatic risk, local recurrence risk and likelihood of benefit from ART. The study published in JAAD showed that the test results can shift or stratify patients across clinically actionable risk thresholds, supporting risk-aligned decisions regarding patient follow-up, surveillance imaging, multidisciplinary referral and ART.

"Managing high-risk SCC patients can be challenging because clinicopathologic staging isn't always precise enough to confidently tailor patients' treatment intensity to their individual level of risk," said lead study author Désirée Ratner, M.D., board-certified dermatologist and Mohs micrographic surgeon, and clinical professor of dermatology at NYU Grossman School of Medicine in New York. "The ability to more precisely distinguish which patients require less intensive management from those who would benefit from additional treatment can help reduce uncertainty for both patients and physicians. This study showed that the DecisionDx-SCC integrated test result, which evaluates patients' tumor biology in combination with their clinicopathologic risk factors, can provide improved, clinically actionable information to support informed discussions about the most appropriate, risk aligned management approach."

The study, titled "Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma," evaluated the enhanced DecisionDx-SCC algorithm in an independent validation cohort of 572 patients with high-risk SCC.

Key study findings include:

- DecisionDx-SCC significantly stratified patients by metastatic and local recurrence risk (p0.0001 for both). In multivariable analysis, the test results provided significant predictive information beyond individual clinicopathologic risk factors for both outcomes.

- Nearly half of patients in the cohort (44.6%) were classified by the i40-GEP test as Class 1A (low risk). This result demonstrated a 97.3% negative predictive value (NPV) and may support greater confidence when considering de-escalation of care in low-risk patients.

- The refined algorithm classified 12.9% of patients as Class 2B (highest risk). These patients had a three-year metastasis-free survival rate of 66.2%, compared with 97.3% for patients with Class 1A (low risk) test results. In multivariable analysis, Class 2B patients were 10.7 times more likely to develop metastasis than Class 1A patients (p0.001), demonstrating strong separation between the test's lowest- and highest-risk results.

- In addition, the Class 2B result identified patients with a high likelihood of benefitting from ART. Patients with Class 2B test results who were treated with ART had an approximately 50% lower median metastatic progression rate at five years than those who did not receive ART. Class 2B ART-treated patients also showed significantly delayed disease progression with decreased acceleration of events compared to Class 2B patients who did not receive ART (p0.01). No significant difference was observed between ART-treated and untreated patients with Class 2A (high risk) test results.

- DecisionDx-SCC demonstrated greater accuracy in predicting metastatic risk than National Comprehensive Cancer Network (NCCN) risk groups and Brigham and Women's Hospital (BWH) staging.

"Continuous innovation at Castle means building on well-established tests as evidence and clinical needs evolve," said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, at Castle Biosciences. "By preserving DecisionDx-SCC's established 40-gene foundation while refining its algorithm to integrate clinicopathologic factors, we can provide more precise, clinically actionable information while maintaining the test's core molecular profile. The study published in JAAD validates these refinements designed to increase confidence in lower-risk results, provide greater clarity for intermediate-risk patients and identify the highest-risk patients most likely to benefit from ART."

About DecisionDx-SCC

DecisionDx-SCC is a gene expression profile (GEP) test that integrates tumor biology and key clinicopathologic risk factors to deliver a refined, personalized risk assessment for patients with cutaneous squamous cell carcinoma (SCC) and one or more high-risk factors. The test provides a patient's individual risk of metastasis and local recurrence, as well as likelihood of benefit from adjuvant radiation therapy (ART). This clinically actionable information is designed to help guide risk-aligned management decisions, including surveillance, imaging, multidisciplinary consultation and consideration of ART.

DecisionDx-SCC has been clinically validated in a multicenter study of patients with localized high-risk cutaneous SCC, in which it was shown to be the strongest predictor of metastasis and local recurrence compared with individual clinicopathologic risk factors and to outperform traditional risk assessment systems. The study adds to a broader evidence base of 20 peer-reviewed publications supporting the test's clinical performance and role in informing individualized patient management. Learn more at DecisionDx-SCC Overview.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning the ability of DecisionDx-SCC to: (i) improve risk stratification and strengthen treatment guidance; (ii) provide more precise and actionable information; (iii) reduce uncertainty in the care journey and support greater confidence when considering de-escalation of management for lower-risk patients; (iv) provide clarity for intermediate-risk patients; (v) identify highest-risk patients who are most likely to benefit from ART; and (vi) inform personalized, risk-aligned decisions involving follow-up, surveillance imaging, multidisciplinary consultation and ART. The words "can," "designed," "may" and similar expressions are intended to identify forward intentions or expectations, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies; actual application of our tests may not provide the aforementioned benefits to certain patients; and the risks set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, our subsequent Quarterly Reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update them, except as may be required by law.

- Ratner D, Singh G, Rizzo JM, et al. Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. Published online August 24, 2026. Accessed August 25, 2026. https://www.jaad.

Hylenr Technologies entdeckt Spuren von Seltenen Erden und eröffnet durch Kernfusion einen neuen technologischen Weg

HYDERABAD, Indien, 9. September 2026 /PRNewswire/ -- Das indische Deep-Tech-Unternehmen Hylenr Technologies hat Hinweise auf die Bildung von Elementen, darunter Seltenerdmetalle, innerhalb künstlich geschaffener Gitterstrukturen gemeldet – und eröffnet damit einen radikal neuen Weg zur Nukleosynthese und zur Herstellung strategischer Werkstoffe.

Die Ergebnisse sind Teil der Arbeit von Hylenr Technologies in den letzten mehr als zehn Jahren auf dem Gebiet der Kernfusionstechnologie auf der Grundlage der Gitter-Einschluss-Fusion (Lattice confinement fusion). Dabei wurden die Ergebnisse durch die Zusammenarbeit des Unternehmens mit führenden internationalen Forschungseinrichtungen validiert.

Ein Teil dieser Arbeit mit dem Titel Nuclear Signatures in a Hydrogen-Loaded Ni–Pd Lattice Confinement System wurde Anfang dieses Monats auf der 27th International Conference on Condensed Matter Nuclear Science (ICCF-27) in Niagara Falls, Kanada, vorgestellt.

Von der Kernenergie zur Nukleosynthese

Die Nukleosynthese ist der Prozess, bei dem Atomkerne umgewandelt werden, um verschiedene Elemente zu erzeugen.

In der Natur findet dies im Inneren von Sternen, Supernovae und anderen extremen astrophysikalischen Umgebungen statt, wo enorme Temperaturen, Drücke und Energiedichten Kernreaktionen antreiben.

Auf der Erde erfordert die Erzeugung oder Umwandlung von Elementen durch nukleare Prozesse in der Regel großtechnische Kernreaktoren, Teilchenbeschleuniger oder hochenergetische Versuchseinrichtungen.

Die Ergebnisse von Hylenr Technologies zeigen einen grundlegend anderen Weg für Kernprozesse und Nukleosynthese in künstlich hergestellten Feststoffen auf, In mit Wasserstoff beladenen Metallgittern schaffen Wechselwirkungen zwischen Wasserstoff, Gitterfehlern, Leerstellen und der lokalen elektronischen Umgebung stark begrenzte Bedingungen, die Kernprozesse innerhalb des Materials selbst ermöglichen.

Dies verlagert die Vorstellung von der Elementbildung von riesigen Hochenergiesystemen hin zu kompakter, künstlich erzeugter Kernenergie.

Signaturen von 32 Elementen nachgewiesen

Im Rahmen einer etwa zweijährigen Materialanalyse hat Hylenr Technologies in Proben aus dem Betriebsbetrieb Signaturen nachgewiesen, die 32 Elementen entsprechen, darunter leichte Elemente, schwere Elemente sowie Edelgase wie Helium, Neon und Argon. Darüber hinaus wurden strategisch wichtige Seltenerdelemente wie Yttrium sowie Aktinide wie Uran nachgewiesen. Die Signaturen werden im Vergleich zur Basis-Charakterisierung derselben Katalysatormaterialprobe vor dem Betrieb, die als Kontrolle dient, ausgewiesen, und jede wird durch mehr als eine der folgenden unabhängigen Techniken bestätigt.

Die Beobachtungen wurden mithilfe mehrerer unabhängiger Analyseverfahren untersucht, darunter:

- Energiedispersive Röntgenspektroskopie (EDX)

- Röntgen-Photoelektronenspektroskopie (XPS)

- Induktiv gekoppelte Plasma-Emissionsspektroskopie (ICP-OES)

- Welllängendispersive Röntgenspektroskopie (WDX)

- Restgasanalyse (RGA)

Hergestellt, nicht abgebaut

Seltenerdelemente stehen im Mittelpunkt vieler der weltweit strategisch wichtigsten Technologien.

Sie sind unverzichtbar für Permanentmagnete, Elektrofahrzeuge, Robotik, Windkraftanlagen, Elektronik, Luft- und Raumfahrtsysteme, Verteidigungsplattformen und fortschrittliche Fertigung.

„Dennoch ist ihre globale Lieferkette nach wie vor stark konzentriert, was zu einer strategischen Abhängigkeit für Länder führt, die den Ausbau von sauberer Energie, der Rüstungsindustrie und der Elektronik der nächsten Generation anstreben", erklärte Ram Ramaseshan, Mitbegründer und Vorstandsmitglied von Hylenr Technologies.

Die Arbeit von Hylenr Technologies weist auf ein völlig anderes Modell hin: ausgewählte Elemente durch künstliche Nukleosynthese herzustellen, anstatt sie ausschließlich aus geologischen Lagerstätten zu gewinnen.

Für Indien könnte dies einen neuen technologischen Weg zur Souveränität bei kritischen Materialien in den Bereichen Verteidigung, Elektronik, Elektromobilität, erneuerbare Energien, Raumfahrt und fortschrittliche Fertigung eröffnen.

Für die Welt eröffnet dies die Möglichkeit, dass der künftige Zugang zu strategischen Elementen nicht nur von deren natürlichen Vorkommen abhängt, sondern auch von unserer Fähigkeit, die Kernumgebungen innerhalb von Materialien so zu gestalten, dass diese Elemente entstehen.

„Was diese Entdeckung so spannend macht, ist die Möglichkeit, Kernfusions-energie und Seltenerdmaterialien auf einer einzigen technischen Nuklearplattform zusammenzuführen ", sagte Siddhartha Durairajan, Mitbegründer und Vorstandsmitglied von Hylenr Technologies.

„Seit Jahrtausenden hängt der Zugang zu einem Element davon ab, ob die Natur es irgendwo in der Erdkruste angereichert hat. Wir arbeiten auf eine ganz andere Zukunft hin – eine, in der wir die materielle Umgebung technisch gestalten können, die zur Erzeugung ausgewählter Elemente erforderlich ist."

Investorenbeziehungen

Share this article

Innocan Pharma Announces Private Placement of Units

HERZLIYA, Israel and CALGARY, Alberta, Sept. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a private placement of up to 535,000 units of the Company (the "Units") at a price of C$1.87 per Unit for gross proceeds up to C$1,000,000 (the "Offering"). The Offering is expected to close on or around September 17, 2026.

Each Unit will be comprised of: (i) one (1) common share in the capital of the Company (each a "Common Share"); and (ii) one (1) common share purchase warrant (each a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$2.50 for a period of three (3) years from the date of issuance; provided that following issuance of the Warrants, if the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange for 30 consecutive trading days equals or exceeds $4.80, the Company can, on written notice to the subscribers or by press release (the "Acceleration Notice") accelerate the expiry date of the Warrants to the date that is 30 days following the date of the Acceleration Notice.

Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes. Innocan also intends to pay a finder's fee equal to 10% in cash and 8% finder's warrants to arm's length finders.

The securities issued to subscribers in connection with the Offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws and the policies of the Canadian Securities Exchange.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or "U.S. Persons", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Innocan

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.

The Company website is www.innocanpharma.com.

For further information, please contact:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+ 15162104025

+972-54-3012842

+442037699377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions relating to the Offering, including the terms, timing, potential completion, and the use of proceeds of the Offering.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: the ability of the Company to satisfy the conditions of closing of the Offering; that the Offering may not be completed on the terms and timeline indicated, or at all; that the Company's use of proceeds of the Offering may differ from those indicated; global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public disclosure and filings which are available under Innocan's profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

SOURCE Innocan Pharma Corporation

Share this article

Deutscher Fernsehpreis 2026: Acht Auszeichnungen für das ZDF

Mainz (ots)

Bei der Verleihung des Deutschen Fernsehpreises 2026 in Köln wurde das ZDF mit insgesamt acht Auszeichnungen geehrt: Bereits bei der "Nacht der Kreativen" am Dienstag, 8. September 2026, gewann Theo Bierkens einen Preis in der Kategorie Beste Kamera Fiktion für den historischen Zweiteiler "Sturm kommt auf". Weitere sieben Preise erhielt das ZDF bei der Fernsehpreisverleihung am Mittwochabend, 9. September 2026.

Zu den ausgezeichneten Produktionen aus der ZDF-Familie zählt in der Kategorie Bester Fernsehfilm/Mehrteiler der Spielfilm " Olivia" von Regisseur Till Endemann (Redaktion: Katharina Görtz, Wolfgang Grundmann, Produktion: Florida Film) über die außergewöhnliche Lebensgeschichte von Olivia Jones, Deutschlands berühmtester Dragqueen. Grell, berührend, humorvoll und politisch verfolgt der Film Olivias Entwicklung hin zu einem Medienstar – und ist gleichzeitig ein Spiegel gesellschaftlicher Veränderung.

Zweifache Auszeichnung: Als beste Comedy-Serie sowie mit dem Förderpreis für das junge Ensemble wurde die ZDFneo-Serie " Chabos" von Arkadij Khaet und Mickey Paatzsch (Buch und Regie; Redaktion: Kristl Philippi, Produktion: BBC Studios) geehrt. In der achtteiligen Serie erfährt der 36-jährige Peppi, dass er nicht zum Klassentreffen eingeladen wurde. Auf der Suche nach Antworten fährt er ins Ruhrgebiet, erinnert sich an sein 16-jähriges Ich und seine besten Freunde am Beginn des folgenschweren Sommers 2006. Doch neben feuchtfröhlichen Erinnerungen lauern abgründige Jugendsünden.

Auch der historische Zweiteiler " Sturm kommt auf" von Regisseur Matti Geschonneck (Redaktion: Daniel Blum, Produktion: Claussen+Putz Filmproduktion/Film AG Produktions für ZDF und ORF) wurde ausgezeichnet: Theo Bierkens erhielt bei der "Nacht der Kreativen" einen Deutschen Fernsehpreis in der Kategorie Beste Kamera Fiktion. Das Historiendrama mit Josef Hader in der Hauptrolle nach dem Roman "Unruhe um einen Friedfertigen" von Oskar Maria Graf thematisiert den aufkommenden Faschismus in der Provinz: Im Zentrum der Handlung steht die so beklemmende wie berührende Geschichte des Schusters Julius Kraus, der eigentlich zurückgezogen am Rande eines bayerischen Dorfes lebt. Immer tiefer gerät er in den Strudel der dramatischen politischen Ereignisse zwischen 1918 und der Machtergreifung Hitlers 1933, bis ihm eine Erbschaft aus den USA und die Offenlegung seiner jüdischen Identität zum Verhängnis werden.

In der Kategorie Beste Comedy/Late Night wurde die "heute-show extra: Next Stop Köster" (Redaktion: Bjørn Christian Mohr; Produktion: Prime Productions) ausgezeichnet. "heute-show"-Politikerschreck Fabian Köster stellt den bayerischen Ministerpräsidenten Markus Söder zum Vier-Augen-Gespräch in besonderer Atmosphäre. Auf acht Quadratmetern liefern sich Söder und Köster einen intensiven Schlagabtausch zu aktuellen Themen.

In der Kategorie Beste Information erhielt die Talkshow " Markus Lanz" einen Deutschen Fernsehpreis (Redaktion: Stefan Bayerl, Susanne Krummacher, Produktion: Mhoch2). Seit 2008 ist das Talkformat fester Bestandteil des ZDF-Programms. Markus Lanz spricht in seiner Talkshow dienstags, mittwochs und donnerstags mit seinen Gästen über aktuelle politische und gesellschaftlich relevante Themen.

In der Kategorie Bestes Infotainment wurde " Terra Xplore mit Leon Windscheid" (Redaktion: Swea Schilling; Produktion: Doclights) ausgezeichnet. Psychologe Dr. Leon Windscheid geht darin Fragen der Psychologie und der mentalen Gesundheit nach. Das Wissenschaftsreportage-Format verbindet spannende Begegnungen, berührende Schicksale und aktuelle Forschung miteinander.

In der Kategorie Beste Doku-Serie wurde " Mesut Özil – Zu Gast bei Freunden" ausgezeichnet (Redaktion: Fabian Farwick, Lisa Reisch, Vanessa Olivier; Produktion: Flare Film). Die dreiteilige "sportstudio"-Produktion rekonstruiert Aufstieg und Fall des Ausnahme-Fußballers Mesut Özil und zeichnet ein umfassendes Bild jener Wochen, die zu Özils Rücktritt aus der Fußball-Nationalmannschaft führten – und zu seiner Entfremdung von Deutschland.

Kontakt

Sie erreichen die ZDF-Kommunikation telefonisch unter 06131 – 70-12108 oder per E-Mail an pressedesk@zdf.de.

Pressefotos

Pressefotos zur Sendung erhalten Sie als Download (nach Log-in), telefonisch unter 06131 – 70-16100 oder per E-Mail unter pressefoto@zdf.de.

Mainz, 9. September 2026

ZDF-Kommunikation

Folgen Sie uns gerne auch auf LinkedIn.

Pressekontakt:

ZDF-Kommunikation

pressedesk@zdf.de

Folgen Sie uns gerne auch bei LinkedIn (https://www.linkedin.com/company/zdf/).

Original-Content von: ZDF, übermittelt durch news aktuell

Reality rules! Deutscher Fernsehpreis 2026 für BR-Koproduktion "Werwölfe - Das Spiel von List und Täuschung"

München (ots)

Der Bayerische Rundfunk freut sich über den Deutschen Fernsehpreis 2026 für "Werwölfe - Das Spiel von List und Täuschung" (BR/SWR/WDR für die ARD Mediathek). Die vom BR federführend verantwortete und von ITV Studios Germany produzierte Reality-Gameshow wurde heute Abend in der Kategorie "Beste Unterhaltung Reality" ausgezeichnet. "Ein teuflisch gutes Verwirrspiel voller List, Poker Faces und schlafloser Nächte, bei dem selbst das Publikum im Dunkeln tappt" hieß es bei der Verleihung in Köln.

Staffel 1 war mit bisher 5,9 Mio. Abrufen ein großer Erfolg in der ARD Mediathek und wurde im Juni bereits mit dem German Entertainment Award ausgezeichnet.

Iris Mayerhofer, Leitung BR-Programmbereich Unterhaltung und Heimat: "Der Deutsche Fernsehpreis für unsere 'Werwölfe' ist eine großartige Auszeichnung und eine starke Bestätigung für den Mut, neue Wege im Entertainment zu gehen. Mit dem federführend vom Bayerischen Rundfunk verantworteten Format haben wir eine moderne, hochspannende Reality-Gameshow für die ARD Mediathek adaptiert und weiterentwickelt, die psychologische Tiefe mit erstklassigem Storytelling vereint und das Publikum begeistert. Mein Dank gilt unseren Teams beim BR und bei ITV Studios Germany sowie unseren Partnern innerhalb der ARD, die dieses außergewöhnliche Format mit Leidenschaft und Innovationskraft möglich gemacht haben."

"Werwölfe - Das Spiel von List und Täuschung" basiert auf dem beliebten Gesellschaftsspiel "Die Werwölfe von Düsterwald" (Originaltitel: "Les Loups-Garous de Thiercelieux"), entwickelt von Philippe des Pallières & Hervé Marly und erschienen bei ASMODEE. Lizenzgeber des Formats ist DreamSpark. In "Werwölfe - Das Spiel von List und Täuschung" ziehen 13 Personen in ein geheimnisvolles Dorf. Drei von ihnen werden zu Werwölfen, die sich als harmlose Dorfbewohner tarnen, doch nur ein Ziel haben: die anderen nach und nach zu eliminieren - ohne selbst enttarnt zu werden. Ein gnadenloses Spiel aus Manipulation und Täuschung beginnt.

Alle 12 Folgen der ersten Staffel sind nach wie vor in der ARD Mediathek verfügbar. Die zweite Staffel startet am 24. September in der ARD Mediathek und wird zudem ab 8. Oktober 2026, immer montags um 23.15 Uhr, mit jeweils drei Folgen im BR Fernsehen ausgestrahlt. Wieder mit dabei ist Schauspieler und Comedian Michael Kessler als charismatischer Sprecher der Reality-Show.

Weitere Auszeichnungen für BR-Produktionen:

Bereits in der "Nacht der Kreativen" am gestrigen Dienstag wurden die BR-Dokuserie "Rise & Fall 1860 München" (Preis für Editorin Xenja Kupin in der Kategorie "Beste Montage Information") sowie die Eurovisions-Show "Silvester-Schlagerbooom 2026 - Die Wunderlichtershow" (ARD/ORF/SRF unter Federführung des BR) in der Kategorie "Beste Regie Unterhaltung" (Preis für Carsten Seibt) mit dem Deutschen Fernsehpreis ausgezeichnet. Mehr Informationen dazu hier.

Fotos über www.ard-foto.de sowie www.br-foto.de; E-Mail: bildmanagement@br.de

Fotos von der Preisverleihung unter https://www.picdrop.com/rtl/GyXHqJdycF

Quelle Mediatheks-Zahlen: AGF Zensus, Global Views

Pressekontakt:

BR-Pressestelle

Wibke Heise

E-Mail: wibke.heise@br.de

Tel.: +49 (0)89 5900-10554

www.br.de/presse

Original-Content von: BR Bayerischer Rundfunk, übermittelt durch news aktuell